News

Galapagos NV announces that the US Food & Drug Administration (FDA) and the European Commission (EC) have granted investigational autotaxin inhibitor GLPG1690 ‘orphan drug…
Read More...

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, is pleased to announce that enrolment into the…
Read More...

AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, announced a research collaboration with a Japanese biopharma company utilizing…
Read More...

Lonza announced that a clinical manufacturing agreement is in place with Rocket Pharmaceuticals, Inc., a clinical-stage company advancing an integrated and sustainable pipeline of…
Read More...

SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, announces it has…
Read More...

Incyte announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD2 study evaluating the safety and efficacy of ruxolitinib cream in adolescent…
Read More...

Kite, a Gilead Company announced that the company’s Marketing Authorization Application (MAA) for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the…
Read More...

Accenture and Google Cloud announced that Google Cloud will be the cloud technology provider for Accenture’s INTIENT life sciences industry platform. The new, multi-year agreement…
Read More...

Alexion Pharmaceuticals, Inc. announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. The acquisition adds two clinical-stage oral small molecule Factor D…
Read More...

The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance…
Read More...

WuXi Biologics has stepped up its efforts in enabling the development of multiple neutralizing antibodies for Novel Coronavirus (2019-nCoV) with its integrated technology platforms.…
Read More...

Conatus Pharmaceuticals Inc. and Histogen Inc., a privately-held regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body,…
Read More...

TILT Biotherapeutics announces that they have signed a license agreement with Biotheus Inc. (“Biotheus”), a privately held Chinese company based in Zhuhai, Guangdong, China. Under the…
Read More...

Roche announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab) in combination…
Read More...

Merck, known as MSD outside the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for DIFICID (fidaxomicin) for…
Read More...

AbbVie and Allergan announced that Allergan has entered into definitive agreements to divest brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase). These agreements are in conjunction…
Read More...

EyePoint Pharmaceuticals and Ocumension Therapeutics announced an exclusive license agreement for the development and commercialization of DEXYCU (dexamethasone intraocular suspension)…
Read More...

Bionetix, a biotech company developing novel oncology drugs; ProQinase, an oncology-focused contract research organization (CRO) recently acquired by Reaction Biology Corporation…
Read More...

Pelican BioThermal announced the further expansion of its worldwide reach into Australia and New Zealand, effective immediately. Wilpak Group International will provide sales and…
Read More...

ATAI Life Sciences AG announced an investment in two separate joint ventures (JV) with DemeRx, a clinical stage pharmaceutical company focused on developing ibogaine and noribogaine for…
Read More...